Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

Panelists discuss how chronic graft-vs-host disease (cGVHD) results from complex biological mechanisms involving inflammation, loss of peripheral tolerance, and fibrotic pathways affecting multiple ...

While mRNA vaccines represent a transformative platform for infectious disease control, their efficacy in antigen-presenting cells (APCs) remains vulnerable to endogenous regulatory networks, ...

Discover a study where researchers have discovered a myeloid-derived antigen-presenting cells population essential for peripherally induced regulatory T cells.

Roche’s Genentech is betting on the Flagship Pioneering–founded company’s discovery platform called DECODE to find new ...

Our body's own defense system not only clears away bacteria and viruses, it can also fight cancer. However, not all tumor ...

New hope: MHH researchers are mobilising the immune system's defence against tumour cells within just two weeks using a two-phase vaccination regimen.

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

Novita Pharmaceuticals, Inc. ("Novita"), a privately held, clinical-stage pharmaceutical company dedicated to developing novel cancer drugs through its proprietary fascin inhibitor technology, today ...

Roche’s Genentech has inked a deal with Repertoire Immune Medicines aimed at discovering and developing T-cell-targeted ...

T-cell activation involves two phases, enabling a more precise immune response. This insight may boost cancer immunotherapy ...

该研究发现肠道中一种特殊的 免疫 细胞类型——耐受性树突状细胞（tolDC）能够降低因接触食物蛋白而引发的免疫反应，从而预防过敏。该研究进一步发现，这些细胞发挥正常功能依赖于表达的 Prdm16 和 RORγt 蛋白，这些细胞功能异常，将更易出现 ...